More quantitative tests should be generated based on plasma to assess HE4 sensitivity in pre-operative and post-operative settings to enable us evaluate the potential of HE4 as a marker in monitoring early stages of breast carcinoma. This evidence concerns the gene WFDC2 and breast carcinoma.